Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Mercè Padró"'
Autor:
Carme de Bolós, Lara Cobler, Rosa Peracaula, Sonia Puig, Mercè Padró, Marta Pérez-Garay, Marta Garrido, Raquel Mejías-Luque
Publikováno v:
Glycoconjugate Journal. 28:99-110
Inflammation of stomach mucosa has been postulated as initiator of gastric carcinogenesis and the presence of pro-inflammatory cytokines can regulate specific genes involved in this process. The cellular expression pattern of glycosyltransferases and
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
Iminosugars are monosaccharide analogues that have been demonstrated to be specific inhibitors for glycosidases and are currently used therapeutically in several human disorders. N-alkylated derivatives of D-fagomine and (2R,3S,4R,5S)-2-(hydroxymethy
Publikováno v:
Hypoxia and Cancer ISBN: 9781461491668
The hypoxic phenotype, characterized by a variety of adaptations that cells make to low oxygen conditions, is a hallmark of solid tumors that serves as both a major challenge and a substantial opportunity in the treatment of cancer. These adaptations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::207a3242badbc52192426a43e50cfb39
https://doi.org/10.1007/978-1-4614-9167-5_11
https://doi.org/10.1007/978-1-4614-9167-5_11
Autor:
Joe W. Gray, Raymond J. Louie, Thomas Holton, Laura J. van't Veer, Denise A. Chan, Frank McCormick, Luika A. Timmerman, Mariia Yuneva, Kornelia Polyak, Stephen P. Ethier, Mercè Padró, Min Hu, Anneleen Daemen
Publikováno v:
Cancer Cell. (4):450-465
SummaryA handful of tumor-derived cell lines form the mainstay of cancer therapeutic development, yielding drugs with an impact typically measured as months to disease progression. To develop more effective breast cancer therapeutics and more readily
Autor:
Brian V. Lananna, Raymond J. Louie, Denise A. Chan, Mercè Padró, Adam J. Krieg, Luika A. Timmerman
Publikováno v:
BMC Cancer
Background About 75–80% of breast tumors express the estrogen receptor alpha (ER-α) and are treated with endocrine-target therapeutics, making this the premier therapeutic modality in the breast cancer clinic. However, acquired resistance is commo